# Trial of Pembrolizumab and Radiotherapy in Melanoma

> **NCT02562625** · PHASE2 · TERMINATED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 17 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02562625
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-11
- **Primary completion:** 2020-03
- **Final completion:** 2021-10
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Slow Recruitment
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562625, "Trial of Pembrolizumab and Radiotherapy in Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02562625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*